Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers
Felix Stickel, Philipp Lutz, Stephan Buch, et al.
Hepatology (2019) Vol. 72, Iss. 1, pp. 88-102
Open Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

Update on NAFLD genetics: From new variants to the clinic
Eric Trépo, Luca Valenti
Journal of Hepatology (2020) Vol. 72, Iss. 6, pp. 1196-1209
Open Access | Times Cited: 313
Immunological mechanisms and therapeutic targets of fatty liver diseases
Hua Wang, Wajahat Z. Mehal, Laura E. Nagy, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 73-91
Open Access | Times Cited: 152
Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives
Szu-Yi Liu, I‐Ting Tsai, Yin-Chou Hsu
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5170-5170
Open Access | Times Cited: 102
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 92
Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond
Marcin Krawczyk, Roman Liebe, Frank Lammert
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1865-1880.e1
Closed Access | Times Cited: 94
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
Yingxin Xian, Jianping Weng, Fen Xu
Chinese Medical Journal (2020) Vol. 134, Iss. 1, pp. 8-19
Open Access | Times Cited: 85
Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors
Tae‐Hwi Schwantes‐An, Rebecca Darlay, Philippe Mathurin, et al.
Hepatology (2020) Vol. 73, Iss. 5, pp. 1920-1931
Open Access | Times Cited: 81
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers
John B. Whitfield, Tae‐Hwi Schwantes‐An, Rebecca Darlay, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 2, pp. 275-282
Open Access | Times Cited: 57
Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis
Xuanxuan Niu, Lin Zhu, Yifan Xu, et al.
BMC Public Health (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 38
Genetics of MASLD: The State of Art Update.
Silvia Sookoian, Yaron Rotman, Luca Valenti
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 11, pp. 2177-2187.e3
Closed Access | Times Cited: 11
Changing landscape of alcohol‐associated liver disease in younger individuals, women, and ethnic minorities
Juan Pablo Arab, Winston Dunn, Gene Y. Im, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1537-1547
Open Access | Times Cited: 9
Alcohol-associated liver cancer
Yaojie Fu, Luca Maccioni, Xin Wei Wang, et al.
Hepatology (2024) Vol. 80, Iss. 6, pp. 1462-1479
Closed Access | Times Cited: 9
Genome-wide association study identifies high-impact susceptibility loci for HCC in North America
Manal M. Hassan, Donghui Li, Younghun Han, et al.
Hepatology (2024) Vol. 80, Iss. 1, pp. 87-101
Open Access | Times Cited: 8
Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1
Hamish Innes, Stephan Buch, Sharon Hutchinson, et al.
Gastroenterology (2020) Vol. 159, Iss. 4, pp. 1276-1289.e7
Open Access | Times Cited: 66
PNPLA3—A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease
X. Charlie Dong
Frontiers in Medicine (2019) Vol. 6
Open Access | Times Cited: 63
17‐Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury
Yanling Ma, Philip M. Brown, Dennis D. Lin, et al.
Hepatology (2020) Vol. 73, Iss. 5, pp. 1701-1716
Open Access | Times Cited: 51
Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets
Cristiana Bianco, Elia Casirati, Francesco Malvestiti, et al.
JHEP Reports (2021) Vol. 3, Iss. 3, pp. 100284-100284
Open Access | Times Cited: 43
Genetic variation inTERTmodifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study
Stephan Buch, Hamish Innes, Philipp Lutz, et al.
Gut (2022) Vol. 72, Iss. 2, pp. 381-391
Open Access | Times Cited: 32
Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
Maral Amangurbanova, Daniel Q. Huang, Rohit Loomba
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 1, pp. 37-51
Open Access | Times Cited: 29
Drug development advances in human genetics‐based targets
X. Zhang, Wenjun Yu, Yan Li, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 6
Epigenetics of alcohol-related liver diseases
Nawras W. Habash, Tejasav S. Sehrawat, Vijay H. Shah, et al.
JHEP Reports (2022) Vol. 4, Iss. 5, pp. 100466-100466
Open Access | Times Cited: 25
Update on genetics and epigenetics in metabolic associated fatty liver disease
Xiaopeng Zhu, Mingfeng Xia, Xin Gao
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 23
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science
Sven Thamm, Marina K. Willwacher, Gary E. Aspnes, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2832-2850
Open Access | Times Cited: 13
MetALD: Does it require a different therapeutic option?
George Marek, Harmeet Malhi
Hepatology (2024) Vol. 80, Iss. 6, pp. 1424-1440
Closed Access | Times Cited: 5
Therapeutic advances in alcohol-associated hepatitis
Gyöngyi Szabó, Mark Thursz, Vijay H. Shah
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1279-1290
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top